Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer

BACKGROUND: Large scale randomized controlled trials have demonstrated that the use of bevacizumab in addition to chemotherapy in patients with advanced non‐small cell lung cancer (NSCLC) conveys significant survival benefits. We explored the clinical impact of a first‐line regimen containing bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Mu, Yuxin, Wang, Yan, Hao, Xuezhi, Zhu, Yixiang, Hu, Xingsheng, Wang, Hongyu, Liu, Peng, Lin, Lin, Wang, Zhijie, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026612/
https://www.ncbi.nlm.nih.gov/pubmed/29768721
http://dx.doi.org/10.1111/1759-7714.12650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026612/
https://www.ncbi.nlm.nih.gov/pubmed/29768721
http://dx.doi.org/10.1111/1759-7714.12650

Ejemplares similares